How does repatha work
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
How Does Repatha Work?
Introduction to Repatha (Evolocumab)
Repatha, also known by its generic name evolocumab, is a fully human monoclonal antibody developed by Amgen. It is primarily used to treat hypercholesterolemia, a condition characterized by high levels of low-density lipoprotein cholesterol (LDL-C) in the blood. Repatha has been approved for use in various regions, including the European Union, and is awaiting approval in other countries such as the USA and Japan.
Mechanism of Action: PCSK9 Inhibition
Targeting PCSK9
Repatha works by targeting a specific protein in the body known as proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a negative regulator of LDL receptors (LDL-R) on the liver cells. Normally, PCSK9 binds to LDL-R, leading to their degradation in the lysosome instead of being recycled back to the cell surface. This process reduces the number of LDL-R available to clear LDL-C from the bloodstream, resulting in higher levels of LDL-C .
Blocking PCSK9
Evolocumab, the active component of Repatha, binds to PCSK9 and inhibits its interaction with LDL-R. By preventing PCSK9 from binding to LDL-R, Repatha allows more LDL-R to be recycled to the liver cell surface. This increases the liver's ability to remove LDL-C from the blood, thereby significantly lowering blood LDL-C levels .
Clinical Efficacy and Usage
LDL-C Reduction
Clinical trials have demonstrated that Repatha can reduce LDL-C levels by approximately 60% in patients who are already on maximal statin therapy. It has shown efficacy both as a monotherapy and in combination with other lipid-lowering agents such as statins and ezetimibe. This makes it a valuable treatment option for patients who cannot achieve their LDL-C targets with statins alone .
Administration and Dosage
Repatha is administered via subcutaneous injection, with recommended dosages of either 140 mg every two weeks or 420 mg once a month . This flexible dosing schedule allows for tailored treatment plans based on patient needs and preferences.
Safety and Tolerability
Clinical Trial Results
Repatha has been well-tolerated in clinical trials, with a safety profile comparable to placebo and other active comparators like ezetimibe . It has not been associated with serious adverse reactions, and its long-term safety continues to be monitored .
Cognitive Function
Importantly, studies have shown that Repatha does not adversely affect cognitive function, addressing a common concern with lipid-lowering therapies. This makes it a safer option for long-term use in managing hypercholesterolemia.
Conclusion
Repatha (evolocumab) is a groundbreaking treatment for hypercholesterolemia, particularly for patients who cannot achieve their LDL-C goals with statins alone. By inhibiting PCSK9, Repatha enhances the liver's ability to clear LDL-C from the blood, significantly lowering LDL-C levels and offering a new avenue for managing cardiovascular risk. Its efficacy, safety, and flexible dosing make it a valuable addition to the arsenal of lipid-lowering therapies.
Sources and full results
Most relevant research papers on this topic